TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30391919

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 27187101

Group type: EXPERIMENTAL
Intervention: S+ (379 ± 31 W)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S- (305 ± 23 W)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RCP (254 ± 26 W)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S+
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RCP
Number of subjects: 12
Study: 25102960

Group type: EXPERIMENTAL
Intervention: N2 multiple-breath washout
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: N2 vital capacity SBW
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DTG-SBW
Number of subjects: 60
Study: 22522918

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lamivudine (3TC)
Number of subjects: 27
Study: 20127230

Group type: EXPERIMENTAL
Intervention: Oral cladribine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18482515

Group type: EXPERIMENTAL
Intervention: High strength GIC (Ketac Molar-3M ESPE)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Resin-modified GIC (Fuji VIII-GC Corp)
Number of subjects: 46
Study: 16137285

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination program in nursing homes
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Nursing homes with pneumococcal immunization programs
Number of subjects: 8000
Study: 12377315

Group type: EXPERIMENTAL
Intervention: High-dose fractionated preoperative radiotherapy (5 x 5 Gy)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 98
Study: 11122794

Group type: EXPERIMENTAL
Intervention: Dose-intensive chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dose therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized studies
Number of subjects: 0
Study: 7572019

Group type: EXPERIMENTAL
Intervention: Polygeline 35 mg.ml‐1 (Haemaccel)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dextran 70 (Macrodex) 60 mg.ml‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ringer's acetate (RAc)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Colloid groups (polygeline, dextran, albumin)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Albumin 40 mg.ml‐1 in saline
Number of subjects: 40
Study: 2157734

Group type: EXPERIMENTAL
Intervention: 1.5% (w/v) NaHCO3
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0.9% (w/v) NaCl
Number of subjects: 25
Study: 7000227

Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole (1-g suppository with premedication and 200 mg t.d.s. orally for 7 days)
Number of subjects: 170

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Culture of the appendix
Number of subjects: 170
Study: 31138301

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (exact dosage and duration not specified)
Number of subjects: 0
Study: 28087506

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg at weeks 0, 4 and every 8 weeks
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Guselkumab 50 mg at weeks 0, 4 and every 8 weeks
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg at weeks 0, 4 and every 8 weeks
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 26177541

Group type: EXPERIMENTAL
Intervention: a‐tPCSPD = 500
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: a‐tPCSPD = 250
Number of subjects: 0

Group type: COMPARATOR
Intervention: sham a‐tPCS
Number of subjects: 0
Study: 24238770

Group type: EXPERIMENTAL
Intervention: Exercise-training plus breathing-retraining and oxygen (n=35)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Exercise-training plus heliox (n=33)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Exercise-training plus oxygen (n=35)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Breathing-retraining plus oxygen
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Exercise-training plus breathing-retraining and oxygen
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Exercise-training plus heliox
Number of subjects: 192
Study: 21161742

Group type: EXPERIMENTAL
Intervention: Intraarticular injection of an IL‐1 inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19067085

Group type: EXPERIMENTAL
Intervention: Culturally tailored navigator program including educational material, phone or in-person contact by language-concordant navigators, patient education, procedure scheduling, translation of bowel preparation, and assistance with transportation and insurance coverage.
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Usual care control group.
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Culturally tailored navigator program.
Number of subjects: 1223
Study: 15996033

Group type: EXPERIMENTAL
Intervention: High dose H(2)RAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard dose proton pump inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose other proton pump inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose omeprazole
Number of subjects: 0
Study: 12590652

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10021302

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (nontreated)
Number of subjects: 32
Study: 8762358

Group type: EXPERIMENTAL
Intervention: Nurse visit with health education (group A)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Nurse visit without health education (group B)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: GP letter (group C)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Comparison of group A and group C
Number of subjects: 799

Group type: COMPARATOR
Intervention: Comparison of group B and group C
Number of subjects: 799

Group type: COMPARATOR
Intervention: Comparison of group A and group B
Number of subjects: 799
Study: 1907907

Group type: EXPERIMENTAL
Intervention: Gabapentin 1,200 mg/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 43
Study: 7066137

Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etomidate (0.1-0.4 mg kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional injections of etomidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous infusion of etomidate
Number of subjects: 0
Study: 31838148

Group type: EXPERIMENTAL
Intervention: Moderate training group (MG)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intensive training group (IG)
Number of subjects: 48
Study: 30597719

Group type: EXPERIMENTAL
Intervention: Medtronic SCS device (primo-implant)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Medtronic SCS device (replacement implant)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: All patients (both groups)
Number of subjects: 402
Study: 28224443

Group type: COMPARATOR
Intervention: SAP (strengthening, agility, and secondary prevention)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SAP+PERT (SAP protocol with the addition of perturbation training)
Number of subjects: 40
Study: 26125923

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Parenteral nutrition (PN)
Number of subjects: 68
Study: 22775239

Group type: EXPERIMENTAL
Intervention: ABT-102 6 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ABT-102 2 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: ABT-102 0.5 mg
Number of subjects: 24
Study: 21156319

Group type: EXPERIMENTAL
Intervention: oxLDL immune complexes (oxLDL-IC)
Number of subjects: 476
Study: 18462100

Group type: EXPERIMENTAL
Intervention: Injectable hormonal contraceptive use
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Not applicable (control group of seroprevalent and seronegative women)
Number of subjects: 1686

Group type: EXPERIMENTAL
Intervention: Plasma virus set point
Number of subjects: 1686
Study: 16778652

Group type: EXPERIMENTAL
Intervention: PMMA implant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Collagen implant
Number of subjects: 60
Study: 15006580

Group type: EXPERIMENTAL
Intervention: Surgery and adjuvant chemotherapy (9 cycles of 5 days every 4 weeks; daily administration of 200 mg/m² folinic acid, 5-fluorouracil starting at 375 mg/m² increasing to 500 mg/m², and CDDP 15 mg/m²)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 205
Study: 11732150

Group type: EXPERIMENTAL
Intervention: Vitamin A fortified biscuits with de-worming treatment
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Vitamin A fortified biscuits without de-worming treatment
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Antihelminthic treatment
Number of subjects: 579

Group type: COMPARATOR
Intervention: Unfortified biscuits
Number of subjects: 579
Study: 9219700

Group type: EXPERIMENTAL
Intervention: Prednisone (0.5 to 0.8 mg/kg/day) and aspirin (100 mg/day)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Prednisone and aspirin
Number of subjects: 202
Study: 8195582

Group type: EXPERIMENTAL
Intervention: Amitriptyline 115 mg/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Alprazolam 3.2 mg/day
Number of subjects: 43
Study: 3591728

Group type: EXPERIMENTAL
Intervention: Zinc-histidine complexes (1:2 ratio)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zinc-histidine complexes (1:12 ratio)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zinc-histidine (15 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Zinc sulfate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zinc preparations (both zinc-histidine and zinc sulfate)
Number of subjects: 10
Study: 29900565

Group type: EXPERIMENTAL
Intervention: GSK2330811
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27665195

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (19 fractions of 3.4 Gy)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Conventional fractionation (39 fractions of 2 Gy)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Hypofractionated treatment
Number of subjects: 820

Group type: COMPARATOR
Intervention: Hypofractionated treatment vs Conventional treatment
Number of subjects: 820
Study: 24964505

Group type: EXPERIMENTAL
Intervention: Oral vitamin K antagonists (VKAs)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Normal cognitive function (MMSE = 24-27)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Disturbances of cognitive function (MMSE < 24)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cognitive function disturbances
Number of subjects: 93
Study: 22079063

Group type: EXPERIMENTAL
Intervention: Single lag screw and arch bar
Number of subjects: 20

Group type: COMPARATOR
Intervention: Two lag screws
Number of subjects: 20
Study: 20026501

Group type: EXPERIMENTAL
Intervention: 6 weeks of abduction treatment
Number of subjects: 128

Group type: COMPARATOR
Intervention: Active-sonographic-surveillance
Number of subjects: 128

Group type: COMPARATOR
Intervention: Both groups (treatment and surveillance)
Number of subjects: 128
Study: 18164001

Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptive pill (ethinylestradiol plus norethisterone)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16816278

Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Enhanced specialty referral
Number of subjects: 1531
Study: 14674822

Group type: EXPERIMENTAL
Intervention: High self-monitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low self-monitors
Number of subjects: 0
Study: 11119090

Group type: EXPERIMENTAL
Intervention: Water containing 2% ethanol for irrigation during TURP
Number of subjects: 100
Study: 9362598

Group type: EXPERIMENTAL
Intervention: Patient education program for high disease activity patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient education program for low disease activity patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group for high disease activity patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group for low disease activity patients
Number of subjects: 0
Study: 1348168

Group type: COMPARATOR
Intervention: 0 mg/70 kg dezocine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.5 mg/70 kg dezocine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5.0 mg/70 kg dezocine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg dezocine
Number of subjects: 10
Study: 3760278

Group type: EXPERIMENTAL
Intervention: Infrared coagulator
Number of subjects: 0

Group type: COMPARATOR
Intervention: CO2 laser
Number of subjects: 0
Study: 28766913

Group type: EXPERIMENTAL
Intervention: PC support with texting (Lactation Advice thru Texting Can Help intervention)
Number of subjects: 58

Group type: COMPARATOR
Intervention: PC support without texting (control)
Number of subjects: 58
Study: 27126971

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg/day for 5 days, started the next day after finishing medroxyprogesterone acetate course (early induction)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg/day for 5 days, started on day 2 of withdrawal bleeding (late induction)
Number of subjects: 90
Study: 24325778

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of Simvastatin and Bezafibrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 23038702

Group type: EXPERIMENTAL
Intervention: Curcumin (1 g/d, n = 46)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (n = 50)
Number of subjects: 96
Study: 19301936

Group type: EXPERIMENTAL
Intervention: niacin extended-release (NER) 500 mg/day in week 1, 1000 mg/day in week 2, and 2000 mg/day in weeks 3-6/aspirin (ASA)
Number of subjects: 276

Group type: COMPARATOR
Intervention: NER/ASA placebo
Number of subjects: 276

Group type: COMPARATOR
Intervention: NER placebo/ASA placebo
Number of subjects: 276
Study: 17493057

Group type: EXPERIMENTAL
Intervention: Pre-treatment methamphetamine use
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Gender, route of administration, and pre-treatment methamphetamine use
Number of subjects: 420
Study: 15448268

Group type: EXPERIMENTAL
Intervention: Technology transfer condition with an interactive distance learning computer training curriculum and individualized distance consultation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 42
Study: 11394684

Group type: EXPERIMENTAL
Intervention: High-level reasoning mechanism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention to distinctive input (ADIT)
Number of subjects: 0
Study: 9722054

Group type: EXPERIMENTAL
Intervention: butorphanol (2 mg) + bupivacaine (0.25%)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: fentanyl (50 microg) + bupivacaine (0.25%)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: sufentanil (15 microg) + bupivacaine (0.25%)
Number of subjects: 109

Group type: COMPARATOR
Intervention: saline + bupivacaine (0.25%)
Number of subjects: 109
Study: 8051795

Group type: EXPERIMENTAL
Intervention: L-627 (biapenem) 6 mg/kg
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: L-627 (biapenem) 12 mg/kg
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: L-627 (biapenem) 5 mg/kg
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: L-627 (biapenem) 20-40 mg/kg
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: L-627 (biapenem)
Number of subjects: 297
Study: 2923084

Group type: EXPERIMENTAL
Intervention: 1000 mg all‐rac‐alpha‐tocopherol and RRR‐gamma‐tocopherol
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Post-gall bladder surgery
Number of subjects: 2
Study: 4913784

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 94
Study: 30878507

Group type: EXPERIMENTAL
Intervention: Gloves-first technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed staff-assisted technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open staff-assisted technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed and open techniques
Number of subjects: 0
Study: 28532478

Group type: EXPERIMENTAL
Intervention: 40ml High Volume Image Guided Injection (HVIGI) with or without corticosteroid
Number of subjects: 96

Group type: COMPARATOR
Intervention: 3ml local anaesthetic sham-control injection
Number of subjects: 96
Study: 25399017

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for cardiovascular mortality
Number of subjects: 5378

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for all-cause mortality
Number of subjects: 5378
Study: 23219175

Group type: EXPERIMENTAL
Intervention: Frequent snoring
Number of subjects: 42244
Study: 21529957

Group type: EXPERIMENTAL
Intervention: pegaptanib 0.3 mg
Number of subjects: 260

Group type: COMPARATOR
Intervention: sham
Number of subjects: 260
Study: 19732281

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (154 mEq/L)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sodium chloride (0.9%) and oral N-acetylcysteine (NAC)
Number of subjects: 93
Study: 22905595

Group type: EXPERIMENTAL
Intervention: Active treatment with high-dose hypoallergenic 6-grass pollen preparation (SCIT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 37
Study: 15828937

Group type: EXPERIMENTAL
Intervention: Sharp debridement
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (minimal granulation tissue)
Number of subjects: 55
Study: 12451325

Group type: EXPERIMENTAL
Intervention: Verapamil 180 mg/day + Trandolapril 2 mg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/day + Nifedipine 20 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (11 normotensive subjects)
Number of subjects: 29
Study: 9710002

Group type: EXPERIMENTAL
Intervention: LBV
Number of subjects: 188

Group type: COMPARATOR
Intervention: AD
Number of subjects: 188
Study: 7874893

Group type: EXPERIMENTAL
Intervention: Experimental formula (Impact) supplemented with arginine, nucleotides, and fish oil
Number of subjects: 296

Group type: COMPARATOR
Intervention: Common use control formula (Osmolite.HN)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Experimental formula (Impact)
Number of subjects: 296
Study: 2172178

Group type: EXPERIMENTAL
Intervention: Dietary fibre supplement (7 g/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 292718

Group type: EXPERIMENTAL
Intervention: Nitrous oxide‐oxygen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 20
Study: 30477789

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl (TE) 250 mg TID
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl (TE) 500 mg TID
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl (TE) 500 mg TID in open-label extension (OLE)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Durable responders (DRs) during the DBTP
Number of subjects: 135
Study: 27426426

Group type: EXPERIMENTAL
Intervention: Health-led FRIENDS intervention
Number of subjects: 1362

Group type: COMPARATOR
Intervention: School-led FRIENDS intervention
Number of subjects: 1362

Group type: COMPARATOR
Intervention: Usual PSHE lessons
Number of subjects: 1362
Study: 25701700

Group type: EXPERIMENTAL
Intervention: 4.375 g/day gluten
Number of subjects: 61

Group type: COMPARATOR
Intervention: Rice starch (placebo)
Number of subjects: 61
Study: 23373881

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 20575400

Group type: EXPERIMENTAL
Intervention: Sheshiliuhuang decoction, 2 times a day for 7 days
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sanjin pills, 3 pills 3 times a day for 7 days
Number of subjects: 92
Study: 19090322

Group type: EXPERIMENTAL
Intervention: APD125 10 mg
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: APD125 40 mg
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: APD125
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 15980934

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin 200 IU/day for 2 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Paracetamol 1500 mg/day for 2 months
Number of subjects: 35
Study: 12803872

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 mug/kg) alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of ivermectin and albendazole
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 10824236

Group type: EXPERIMENTAL
Intervention: HRT (2 mg estradiol valerate and 1 mg cyproterone acetate)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 464
Study: 8667486

Group type: EXPERIMENTAL
Intervention: Power Doppler imaging
Number of subjects: 21

Group type: COMPARATOR
Intervention: Color Doppler imaging
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Neither modality
Number of subjects: 21
Study: 1893709

Group type: COMPARATOR
Intervention: Oral contraceptive use before pregnancy
Number of subjects: 846

Group type: COMPARATOR
Intervention: Oral contraceptive use in early pregnancy
Number of subjects: 846